A new study co-led by WEHI has found a simple blood test can help identify the early-stage testicular cancer patients who are ...
Based on the NCCN 1.2026 guidelines for the management of CSI seminoma, surveillance is strongly preferred for pT1-pT3 tumors, and the NCCN does not recommend risk-adapted treatment for CSI seminoma ...
Cornell researchers have confirmed that a previously identified biomarker for detecting the presence of malignant testicular germ cell tumors—the most common solid cancers in young men—has the ...
The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...
Testicular germ cell tumors are on the rise in the US. The incidence among Hispanic men now surpasses that of non-Hispanic White men, who have historically had the highest incidence. The incidence of ...
Phase I trial of chidamide, an oral HDAC inhibitor, in combination with oral etoposide in patients with refractory/recurrent neuroblastoma. Type II RAF inhibitor tovorafenib in relapsed/refractory ...
(a) Overgrowth of round cells with eosinophilic cytoplasm in a sheet-like growth pattern. Note the residual teratomatous (glandular) component in the right upper corner. (b) High-power view of the ...
Two of the researchers were also the first to create ovarian organoids from mouse embryonic stem cells, in 2021.
To offer minimized risk-adapted adjuvant treatment on a nationwide basis for patients with clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT). The aim was to reduce the risk of ...
Testicular cancer is relatively rare with only 8,850 cases expected this year in the United States. A majority of testicular cancer, 95 percent of all cases, begins in testicular germ cells, which are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results